Rigel Reports First Quarter 2022 Financial Results and Provides Business Update
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2022, including sales of...
Stay updated with breaking news from Webcast Today. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2022, including sales of...
Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis - read this article along with other careers information, tips and advice on BioSpace
Interim Analysis in Phase 2 CANAL Trial Showed Primary Efficacy Endpoint of Cough Reduction in Idiopathic Pulmonary Fibrosis was Highly Statistica...
CAP-1002 Cell Therapy Programs -Pivotal Phase 3, HOPE-3 Trial Initiation Underway- -Entered Exclusive Partnership with Nippon Shinyaku for...
25.02.2022 - Conference Call and Webcast Today at 8:30 a.m. ETU.S. FDA lifts clinical hold on IND application for COVAXIN (BBV152), clearing the pathway for Phase 2/3 clinical trial in support of a BLA submissionEngagement with U.S. FDA to advance pediatric EUA ...